FXR1 Antibody (YA6302)

Cat. No.: HY-P86610: Data Sheet User Guide for Antibodies
FAQs
Technical Support

FXR1 Antibody (YA6302) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to FXR1.

For research use only. We do not sell to patients.

Size	Stock	Quantity
20 μL	Get quote 2 - 3 Weeks 1 - 2 Weeks 3 - 4 Weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
50 μL	Get quote 2 - 3 Weeks 1 - 2 Weeks 3 - 4 Weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
100 μL	Get quote 2 - 3 Weeks 1 - 2 Weeks 3 - 4 Weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
250 μL	Get quote

Synthetic products have potential research and development risk.

or Bulk Inquiry

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

FXR1 Antibody (YA6302) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to FXR1.

Host

Rabbit

Clonality

Monoclonal

Molecular Weight

Predicted band size: 70 kDa;

Observed band size: 70-84 kDa

Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.

Species Reactivity

Human, Mouse, Rat

SwissProt ID

P51114

Gene ID

8087 [NCBI]

Application &
Dilution Ratio

Application	Dilution Ratio
IHC-P IHC-P: Immunohistochemistry-Paraffin	1:200-1000
WB WB: Western Blot	1:1000-5000
ICC/IF ICC/IF: Immunocytochemistry/Immunofluorescence	1:200-1000
ELISA ELISA: Enzyme Linked Immunosorbent Assay	1:5000-20000
IP IP: Immunoprecipitation	1:50-200

Purity	Protein A	Conjugation	Non-conjugated
Modification	Unmodified	Isotype	IgG

Appearance

Liquid

Formulation

Supplied in PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：mRNA-binding protein that acts as a regulator of mRNAs translation and/or stability, and which is required for various processes, such as neurogenesis, muscle development and spermatogenesis (PubMed:17382880, PubMed:20417602, PubMed:30067974, PubMed:34731628, PubMed:35989368, PubMed:36306353). Specifically binds to AU-rich elements (AREs) in the 3'-UTR of target mRNAs (PubMed:17382880, PubMed:34731628). Promotes formation of some phase-separated membraneless compartment by undergoing liquid-liquid phase separation upon binding to AREs-containing mRNAs, leading to assemble mRNAs into cytoplasmic ribonucleoprotein granules that concentrate mRNAs with associated regulatory factors (By similarity). Required to activate translation of stored mRNAs during late spermatogenesis: acts by undergoing liquid-liquid phase separation to assemble target mRNAs into cytoplasmic ribonucleoprotein granules that recruit translation initiation factor EIF4G3 to activate translation of stored mRNAs in late spermatids (By similarity). Promotes translation of MYC transcripts by recruiting the eIF4F complex to the translation start site (PubMed:34731628). Acts as a negative regulator of inflammation in response to IL19 by promoting destabilization of pro-inflammatory transcripts (PubMed:30067974). Also acts as an inhibitor of inflammation by binding to TNF mRNA, decreasing TNF protein production (By similarity). Acts as a negative regulator of AMPA receptor GRIA2/GluA2 synthesis during long-lasting synaptic potentiation of hippocampal neurons by binding to GRIA2/GluA2 mRNA, thereby inhibiting its translation (By similarity). Regulates proliferation of adult neural stem cells by binding to CDKN1A mRNA and promoting its expression (By similarity). Acts as a regulator of sleep and synaptic homeostasis by regulating translation of transcripts in neurons (By similarity). Required for embryonic and postnatal development of muscle tissue by undergoing liquid-liquid phase separation to assemble target mRNAs into cytoplasmic ribonucleoprotein granules (PubMed:30770808). Involved in the nuclear pore complex localization to the nuclear envelope by preventing cytoplasmic aggregation of nucleoporins: acts by preventing ectopic phase separation of nucleoporins in the cytoplasm via a microtubule-dependent mechanism (PubMed:32706158). Plays a role in the stabilization of PKP2 mRNA and therefore protein abundance, via its interaction with PKP3 (PubMed:25225333). May also do the same for PKP2, PKP3 and DSP via its interaction with PKP1 (PubMed:25225333). Forms a cytoplasmic messenger ribonucleoprotein (mRNP) network by packaging long mRNAs, serving as a scaffold that recruits proteins and signaling molecules. This network facilitates signaling reactions by maintaining proximity between kinases and substrates, crucial for processes like actomyosin reorganization (PubMed:39106863)

Subcellular Localization：Cytoplasm, Cytoplasmic ribonucleoprotein granule; Cytoplasm, Stress granule; Cytoplasm; Cell projection, dendrite; Cell projection, dendritic spine; Cell projection, axon; Nucleus envelope; Postsynapse

Expression：
Tissue_specificity:It was expressed in all tissues examined, including the heart, brain, kidneys, and testes (PubMed:7781595, PubMed:9259278) . In the brain, it was found in higher concentrations in neurons, particularly in Purkinje cells at the granular-molecular junction (protein level) (PubMed:9259278) .

Induction:By Interleukin-19 (IL19)

Isoforms & Post-Translational Modification：P51114 has 3 isomers: P51114-1: 69721 Da (predicted); P51114-2: 60792 Da (predicted); P51114-3: 59920 Da (predicted).
Phosphorylation at Ser-420 by PAK1 promotes its relocalization to stress granules and activity (PubMed:20417602). Phosphorylated by MAPK1/ERK2, promoting subsequent phosphorylation by GSK3B (By similarity). Phosphorylated by GSK3B, promoting ubiquitination and degradation by the proteasome (By similarity);Ubiquitinated by the SCF(FBXO4) complex, leading to its degradation by the proteasome: ubiquitination by the SCF(FBXO4) complex takes place following phosphorylation by GSK3B (PubMed:29142209). Ubiquitinated and degraded in a GSK3B-dependent manner in during both scaling and sleep deprivation (By similarity). Ubiquitinated via 'Lys-63'-linked ubiquitin, leading to its degradation: interaction with CEP63 inhibits 'Lys-63'-linked ubiquitination (PubMed:35989368)

Subunit：Homodimer (via CC domains); homodiremization is required for FXR1-network nucleation (PubMed:39106863). Interacts with FMR1 (PubMed:11157796, PubMed:7489725, PubMed:8668200). Interacts with FRX2 (PubMed:7489725). Interacts with TDRD3 (PubMed:18664458). Interacts with HABP4 (PubMed:21771594). Interacts with CYFIP2 but not with CYFIP1 (By similarity). Interacts with EIF4G3; promoting translation of target mRNAs (By similarity). Interacts with ELAVL1 (PubMed:30067974). Interacts with CEP63; inhibiting 'Lys-63'-linked ubiquitination (PubMed:35989368). Interacts with PKP3; the interaction facilitates the binding of PKP3 to PKP2 mRNA (PubMed:25225333). Interacts with PKP1; the interaction may facilitate the binding of PKP1 to PKP2, PKP3 and DSP mRNA (PubMed:25225333)

Synonyms

Fragile X mental retardation syndrome-related protein 1; hFXR1p;

Documentation

User Guide for Antibodies (1077 KB)